Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

miRNAs and T cell-mediated Immune Response in Disease

Holvoet P.

Narrative Review on Type 1 Diabetes, Type 2 Diabetes, Autoimmune Research, published in Yale J Biol Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Yale J Biol Med (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40589938
PMCID
PMC12204035
DOI
10.59249/payj6872
Citations
2

Abstract (original English)

We reviewed the role of miRNAs in the regulation of T cell differentiation and function in cardiometabolic inflammatory diseases, such as obesity, type 2 diabetes, atherosclerosis, and autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, asthma, and cancer. Cardiometabolic diseases, type 1 diabetes, and rheumatoid arthritis are characterized by miRNA expression profiles that favor the differentiation of T helper 1 and 17 cells and cytotoxic cells and a decrease in T helper 2 cells, regulatory T cells, and myeloid-derived suppressor cells. Asthma is characterized by changes in miRNAs that favor the differentiation of T helper 2 cells. Finally, cancer is characterized by miRNA profiles that cause a decrease in T helper 1 and 17 cells and cytotoxic cells and an increase in T helper 2 cells, regulatory T cells, and myeloid-derived suppressor cells. In particular, differences in the expression of miR-155 and a cluster containing Let-7, miR-10a, miR-17-92, miR-34a, miR-142, and miR-150 may determine whether the balance flips towards cytotoxicity or immunosuppression. High levels of miR-21 and miR-29 and low levels of miR-150 are associated with T cell profiles that protect against inflammatory and autoimmune diseases associated with tissue damage but also induce tumor growth. All these miRNAs were found to be associated with disease progression and/or response to thera

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
T-LymphocytesAnimalsHumansNeoplasmsAutoimmune DiseasesMicroRNAsImmunity, Cellular

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research